The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Anticancer Drugs-Global Market Insights and Sales Trends 2025
Synopsis
Anticancer drugs are medications used to treat cancer by targeting and killing cancer cells or inhibiting their growth.
The global Anticancer Drugs market size is expected to reach US$ 112910 million by 2029, growing at a CAGR of 3.7% from 2023 to 2029. The market is mainly driven by the significant applications of Anticancer Drugs in various end use industries. The expanding demands from the Lung Cancer, Breast Cancer, Leukemia and Colorectal Cancer, are propelling Anticancer Drugs market. Cytotoxic Drugs (Alkylating Agents, and Antimetabolites), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Targeted Drugs (Monoclonal Antibodies and Tyrosine Kinase Inhibitors) segment is estimated at % CAGR for the next seven-year period.
The market for anticancer drugs is driven by the increasing incidence of cancer and the growing demand for effective and personalized cancer treatments. The development of targeted and immunotherapeutic drugs further boosts the market growth.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Anticancer Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Anticancer Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Anticancer Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Anticancer Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Anticancer Drugs covered in this report include F. Hoffmann-La Roche Ltd, Eli Lilly and Company, CELGENE CORPORATION, Novartis AG, Pfizer Inc, Amgen Inc, Bayer AG, AstraZeneca and Takeda Pharmaceutical Company Limited, etc.
The global Anticancer Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
F. Hoffmann-La Roche Ltd
Eli Lilly and Company
CELGENE CORPORATION
Novartis AG
Pfizer Inc
Amgen Inc
Bayer AG
AstraZeneca
Takeda Pharmaceutical Company Limited
Merck & Co.
Global Anticancer Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Anticancer Drugs market, Segment by Type:
Cytotoxic Drugs (Alkylating Agents, and Antimetabolites)
Targeted Drugs (Monoclonal Antibodies and Tyrosine Kinase Inhibitors)
Hormonal Drugs
Global Anticancer Drugs market, by Application
Lung Cancer
Breast Cancer
Leukemia
Colorectal Cancer
Other
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Anticancer Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Anticancer Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Anticancer drugs are medications used to treat cancer by targeting and killing cancer cells or inhibiting their growth.
The global Anticancer Drugs market size is expected to reach US$ 112910 million by 2029, growing at a CAGR of 3.7% from 2023 to 2029. The market is mainly driven by the significant applications of Anticancer Drugs in various end use industries. The expanding demands from the Lung Cancer, Breast Cancer, Leukemia and Colorectal Cancer, are propelling Anticancer Drugs market. Cytotoxic Drugs (Alkylating Agents, and Antimetabolites), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Targeted Drugs (Monoclonal Antibodies and Tyrosine Kinase Inhibitors) segment is estimated at % CAGR for the next seven-year period.
The market for anticancer drugs is driven by the increasing incidence of cancer and the growing demand for effective and personalized cancer treatments. The development of targeted and immunotherapeutic drugs further boosts the market growth.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Anticancer Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Anticancer Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Anticancer Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Anticancer Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Anticancer Drugs covered in this report include F. Hoffmann-La Roche Ltd, Eli Lilly and Company, CELGENE CORPORATION, Novartis AG, Pfizer Inc, Amgen Inc, Bayer AG, AstraZeneca and Takeda Pharmaceutical Company Limited, etc.
The global Anticancer Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
F. Hoffmann-La Roche Ltd
Eli Lilly and Company
CELGENE CORPORATION
Novartis AG
Pfizer Inc
Amgen Inc
Bayer AG
AstraZeneca
Takeda Pharmaceutical Company Limited
Merck & Co.
Global Anticancer Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Anticancer Drugs market, Segment by Type:
Cytotoxic Drugs (Alkylating Agents, and Antimetabolites)
Targeted Drugs (Monoclonal Antibodies and Tyrosine Kinase Inhibitors)
Hormonal Drugs
Global Anticancer Drugs market, by Application
Lung Cancer
Breast Cancer
Leukemia
Colorectal Cancer
Other
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Anticancer Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Anticancer Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Anticancer Drugs Market Overview
1.1 Anticancer Drugs Product Overview
1.2 Anticancer Drugs Market Segment by Type
1.2.1 Cytotoxic Drugs (Alkylating Agents, and Antimetabolites)
1.2.2 Targeted Drugs (Monoclonal Antibodies and Tyrosine Kinase Inhibitors)
1.2.3 Hormonal Drugs
1.3 Global Anticancer Drugs Market Size by Type
1.3.1 Global Anticancer Drugs Market Size Overview by Type (2018-2029)
1.3.2 Global Anticancer Drugs Historic Market Size Review by Type (2018-2023)
1.3.3 Global Anticancer Drugs Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Anticancer Drugs Sales Breakdown by Type (2018-2023)
1.4.2 Europe Anticancer Drugs Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Anticancer Drugs Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Anticancer Drugs Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Anticancer Drugs Sales Breakdown by Type (2018-2023)
2 Global Anticancer Drugs Market Competition by Company
2.1 Global Top Players by Anticancer Drugs Sales (2018-2023)
2.2 Global Top Players by Anticancer Drugs Revenue (2018-2023)
2.3 Global Top Players by Anticancer Drugs Price (2018-2023)
2.4 Global Top Manufacturers Anticancer Drugs Manufacturing Base Distribution, Sales Area, Product Type
2.5 Anticancer Drugs Market Competitive Situation and Trends
2.5.1 Anticancer Drugs Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Anticancer Drugs Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Anticancer Drugs as of 2022)
2.7 Date of Key Manufacturers Enter into Anticancer Drugs Market
2.8 Key Manufacturers Anticancer Drugs Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Anticancer Drugs Status and Outlook by Region
3.1 Global Anticancer Drugs Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Anticancer Drugs Historic Market Size by Region
3.2.1 Global Anticancer Drugs Sales in Volume by Region (2018-2023)
3.2.2 Global Anticancer Drugs Sales in Value by Region (2018-2023)
3.2.3 Global Anticancer Drugs Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Anticancer Drugs Forecasted Market Size by Region
3.3.1 Global Anticancer Drugs Sales in Volume by Region (2024-2029)
3.3.2 Global Anticancer Drugs Sales in Value by Region (2024-2029)
3.3.3 Global Anticancer Drugs Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Anticancer Drugs by Application
4.1 Anticancer Drugs Market Segment by Application
4.1.1 Lung Cancer
4.1.2 Breast Cancer
4.1.3 Leukemia
4.1.4 Colorectal Cancer
4.1.5 Other
4.2 Global Anticancer Drugs Market Size by Application
4.2.1 Global Anticancer Drugs Market Size Overview by Application (2018-2029)
4.2.2 Global Anticancer Drugs Historic Market Size Review by Application (2018-2023)
4.2.3 Global Anticancer Drugs Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Anticancer Drugs Sales Breakdown by Application (2018-2023)
4.3.2 Europe Anticancer Drugs Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Anticancer Drugs Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Anticancer Drugs Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Anticancer Drugs Sales Breakdown by Application (2018-2023)
5 North America Anticancer Drugs by Country
5.1 North America Anticancer Drugs Historic Market Size by Country
5.1.1 North America Anticancer Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Anticancer Drugs Sales in Volume by Country (2018-2023)
5.1.3 North America Anticancer Drugs Sales in Value by Country (2018-2023)
5.2 North America Anticancer Drugs Forecasted Market Size by Country
5.2.1 North America Anticancer Drugs Sales in Volume by Country (2024-2029)
5.2.2 North America Anticancer Drugs Sales in Value by Country (2024-2029)
6 Europe Anticancer Drugs by Country
6.1 Europe Anticancer Drugs Historic Market Size by Country
6.1.1 Europe Anticancer Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Anticancer Drugs Sales in Volume by Country (2018-2023)
6.1.3 Europe Anticancer Drugs Sales in Value by Country (2018-2023)
6.2 Europe Anticancer Drugs Forecasted Market Size by Country
6.2.1 Europe Anticancer Drugs Sales in Volume by Country (2024-2029)
6.2.2 Europe Anticancer Drugs Sales in Value by Country (2024-2029)
7 Asia-Pacific Anticancer Drugs by Region
7.1 Asia-Pacific Anticancer Drugs Historic Market Size by Region
7.1.1 Asia-Pacific Anticancer Drugs Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Anticancer Drugs Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Anticancer Drugs Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Anticancer Drugs Forecasted Market Size by Region
7.2.1 Asia-Pacific Anticancer Drugs Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Anticancer Drugs Sales in Value by Region (2024-2029)
8 Latin America Anticancer Drugs by Country
8.1 Latin America Anticancer Drugs Historic Market Size by Country
8.1.1 Latin America Anticancer Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Anticancer Drugs Sales in Volume by Country (2018-2023)
8.1.3 Latin America Anticancer Drugs Sales in Value by Country (2018-2023)
8.2 Latin America Anticancer Drugs Forecasted Market Size by Country
8.2.1 Latin America Anticancer Drugs Sales in Volume by Country (2024-2029)
8.2.2 Latin America Anticancer Drugs Sales in Value by Country (2024-2029)
9 Middle East and Africa Anticancer Drugs by Country
9.1 Middle East and Africa Anticancer Drugs Historic Market Size by Country
9.1.1 Middle East and Africa Anticancer Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Anticancer Drugs Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Anticancer Drugs Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Anticancer Drugs Forecasted Market Size by Country
9.2.1 Middle East and Africa Anticancer Drugs Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Anticancer Drugs Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 F. Hoffmann-La Roche Ltd
10.1.1 F. Hoffmann-La Roche Ltd Company Information
10.1.2 F. Hoffmann-La Roche Ltd Introduction and Business Overview
10.1.3 F. Hoffmann-La Roche Ltd Anticancer Drugs Sales, Revenue and Gross Margin (2018-2023)
10.1.4 F. Hoffmann-La Roche Ltd Anticancer Drugs Products Offered
10.1.5 F. Hoffmann-La Roche Ltd Recent Development
10.2 Eli Lilly and Company
10.2.1 Eli Lilly and Company Company Information
10.2.2 Eli Lilly and Company Introduction and Business Overview
10.2.3 Eli Lilly and Company Anticancer Drugs Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Eli Lilly and Company Anticancer Drugs Products Offered
10.2.5 Eli Lilly and Company Recent Development
10.3 CELGENE CORPORATION
10.3.1 CELGENE CORPORATION Company Information
10.3.2 CELGENE CORPORATION Introduction and Business Overview
10.3.3 CELGENE CORPORATION Anticancer Drugs Sales, Revenue and Gross Margin (2018-2023)
10.3.4 CELGENE CORPORATION Anticancer Drugs Products Offered
10.3.5 CELGENE CORPORATION Recent Development
10.4 Novartis AG
10.4.1 Novartis AG Company Information
10.4.2 Novartis AG Introduction and Business Overview
10.4.3 Novartis AG Anticancer Drugs Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Novartis AG Anticancer Drugs Products Offered
10.4.5 Novartis AG Recent Development
10.5 Pfizer Inc
10.5.1 Pfizer Inc Company Information
10.5.2 Pfizer Inc Introduction and Business Overview
10.5.3 Pfizer Inc Anticancer Drugs Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Pfizer Inc Anticancer Drugs Products Offered
10.5.5 Pfizer Inc Recent Development
10.6 Amgen Inc
10.6.1 Amgen Inc Company Information
10.6.2 Amgen Inc Introduction and Business Overview
10.6.3 Amgen Inc Anticancer Drugs Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Amgen Inc Anticancer Drugs Products Offered
10.6.5 Amgen Inc Recent Development
10.7 Bayer AG
10.7.1 Bayer AG Company Information
10.7.2 Bayer AG Introduction and Business Overview
10.7.3 Bayer AG Anticancer Drugs Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Bayer AG Anticancer Drugs Products Offered
10.7.5 Bayer AG Recent Development
10.8 AstraZeneca
10.8.1 AstraZeneca Company Information
10.8.2 AstraZeneca Introduction and Business Overview
10.8.3 AstraZeneca Anticancer Drugs Sales, Revenue and Gross Margin (2018-2023)
10.8.4 AstraZeneca Anticancer Drugs Products Offered
10.8.5 AstraZeneca Recent Development
10.9 Takeda Pharmaceutical Company Limited
10.9.1 Takeda Pharmaceutical Company Limited Company Information
10.9.2 Takeda Pharmaceutical Company Limited Introduction and Business Overview
10.9.3 Takeda Pharmaceutical Company Limited Anticancer Drugs Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Takeda Pharmaceutical Company Limited Anticancer Drugs Products Offered
10.9.5 Takeda Pharmaceutical Company Limited Recent Development
10.10 Merck & Co.
10.10.1 Merck & Co. Company Information
10.10.2 Merck & Co. Introduction and Business Overview
10.10.3 Merck & Co. Anticancer Drugs Sales, Revenue and Gross Margin (2018-2023)
10.10.4 Merck & Co. Anticancer Drugs Products Offered
10.10.5 Merck & Co. Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Anticancer Drugs Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Anticancer Drugs Industrial Chain Analysis
11.4 Anticancer Drugs Market Dynamics
11.4.1 Anticancer Drugs Industry Trends
11.4.2 Anticancer Drugs Market Drivers
11.4.3 Anticancer Drugs Market Challenges
11.4.4 Anticancer Drugs Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Anticancer Drugs Distributors
12.3 Anticancer Drugs Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
